The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials.

Wang, Fengyun; Li, Yiming; Wang, Bingqing; Li, Jianguo; Peng, Zhiyong

Wang, Fengyun; Li, Yiming; Wang, Bingqing; Li, Jianguo; Peng, Zhiyong.

Afiliación

Wang F; Department of Critical Care Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province, China.
Li Y; Clinical Research Center of Hubei Critical Care Medicine, Wuhan, 430071, Hubei, China.
Wang B; Department of Critical Care Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province, China.
Li J; Clinical Research Center of Hubei Critical Care Medicine, Wuhan, 430071, Hubei, China.
Peng Z; Department of Critical Care Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province, China.

Crit Care ; 27(1): 31, 2023 01 20.

Article en En | MEDLINE | ID: mdl-36670442

Asunto(s)

COVID-19; Células Madre Mesenquimatosas; Síndrome de Dificultad Respiratoria; Animales; Humanos; Ensayos Clínicos Controlados Aleatorios como Asunto; Síndrome de Dificultad Respiratoria/terapia

Palabras clave

Acute lung injury; Acute respiratory distress syndrome; Cell transplantation; Coronavirus disease 2019; Mesenchymal stromal cells

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome de Dificultad Respiratoria / Células Madre Mesenquimatosas / COVID-19 Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies / Systematic_reviews Límite: Animals / Humans Idioma: En Revista: Crit Care Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google